ZEISS Vision Care US Names Healthcare Industry Veteran Gary Rosenblum as President and Chief Executive Officer
HEBRON, Ky.--(BUSINESS WIRE)-- ZEISS Vision Care, one of the world's leading manufacturers of eyeglass lenses and ophthalmic instruments, announced today that Gary Rosenblum has been named President and Chief Executive Officer of ZEISS Vision Care US, effective June 16, 2025. Rosenblum brings relevant senior leadership experience at Demant, Johnson & Johnson, Abbott and Pfizer to his new role. He succeeds Jens Boy, who has spent more than a decade driving the ZEISS Vision Care business in North America, and will depart the company in pursuit of new opportunities on June 30, 2025.
Rosenblum joins ZEISS following more than eight years at Oticon, a division of Demant, where he served as President for US Hearing Aids and led efforts to bring the company's life-changing hearing solutions to Americans with mild-to-severe hearing loss. Under his leadership, Oticon achieved outstanding results in terms of growing market share and increasing revenue, driven by new approaches in sales, talent development and transformation. Before that, Rosenblum led the Enterprise Customer Team at Johnson & Johnson, working with the largest hospital systems on the West Coast. He's also served as Director, Global Strategic Marketing at Abbott, leading the charge in the worldwide commercialization of the company's Diabetes Care portfolio.
'Gary's hands-on experience in highly relevant healthcare roles and his proven track record of success make him an excellent fit to join the ZEISS Vision Care team,' said Sven Hermann, CEO ZEISS Consumer Markets. 'With Gary at the helm, I am confident we will continue our positive momentum and maintain ZEISS' leadership in the US market. I am incredibly grateful for the role Jens played in transforming ZEISS Vision Care in North America over the past ten years and wish him the best in his future endeavors.'
In his role as president and CEO, Rosenblum will focus on growing ZEISS Vision Care US, both in terms of the core business and future opportunities. Driven by a commitment to protect and improve eye health, he is passionate about continuing the legacy of innovation that has guided ZEISS for more than 179 years.
'I am thrilled to join ZEISS Vision Care and continue to build on the company's mission of delivering industry-leading optical innovations to eyecare professionals and millions of Americans,' said Rosenblum. 'I am already impressed with our incredible team in the US and their commitment to excellence. I'd like to thank Jens for his support with this transition and look forward to continuing his record of success for the company.'
About ZEISS
ZEISS is an internationally leading technology enterprise operating in the fields of optics and optoelectronics. In the previous fiscal year, the ZEISS Group generated annual revenue totaling 10 billion euros in its four segments Semiconductor Manufacturing Technology, Industrial Quality & Research, Medical Technology and Consumer Markets (status: 30 September 2023).
For its customers, ZEISS develops, produces and distributes highly innovative solutions for industrial metrology and quality assurance, microscopy solutions for the life sciences and materials research, and medical technology solutions for diagnostics and treatment in ophthalmology and microsurgery. The name ZEISS is also synonymous with the world's leading lithography optics, which are used by the chip industry to manufacture semiconductor components. There is global demand for trendsetting ZEISS brand products such as eyeglass lenses, camera lenses and binoculars.
With a portfolio aligned with future growth areas like digitalization, healthcare and Smart Production and a strong brand, ZEISS is shaping the future of technology and constantly advancing the world of optics and related fields with its solutions. The company's significant, sustainable investments in research and development lay the foundation for the success and continued expansion of ZEISS' technology and market leadership. ZEISS invests 15 percent of its revenue in research and development – this high level of expenditure has a long tradition at ZEISS and is also an investment in the future.
With over 43,000 employees, ZEISS is active globally in almost 50 countries with around 30 production sites, 60 sales and service companies and 27 research and development facilities (status: 30 September 2023). Founded in 1846 in Jena, the company is headquartered in Oberkochen, Germany. The Carl Zeiss Foundation, one of the largest foundations in Germany committed to the promotion of science, is the sole owner of the holding company, Carl Zeiss AG.
ZEISS Vision Care is one of the world's leading manufacturers of eyeglass lenses and ophthalmic instruments. The unit is allocated to the Consumer Markets segment and develops and produces offerings for the entire eyeglass value chain that are distributed globally under the ZEISS brand.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
17 minutes ago
- Business Insider
Stock Market News Review: SPY, QQQ Rise on ‘Weak' Iran Retaliation, July Rate Cut Odds Jump
Both the S&P 500 (SPX) and the Nasdaq 100 (NDX) closed higher following Iran's missile strike on a U.S. military base in Qatar. The attack was Iran's response to U.S. strikes on three of its nuclear sites over the weekend. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Despite Iran's retaliation, the market remained strong while oil prices dropped. That's because the attack resulted in zero casualties and didn't disrupt any oil infrastructure or supply chain locations. In addition, Qatar was able to intercept all of the missiles and was informed by Iran of the strikes before they actually occurred. As a result, it appears that Iran's retaliation was more symbolic than aggressive, signaling that the country is closer to taking a seat at the negotiation table. President Trump called the move 'a very weak response.' 'The base that was targeted in the attack by the powerful Iranian forces was far from urban facilities and residential areas in Qatar,' said Iran's Supreme National Security Council. However, oil prices still remain elevated compared to the start of the war on June 13. 'To The Department of Energy: DRILL, BABY, DRILL!!! And I mean NOW!!!' said Trump in a Truth Social post this morning, encouraging domestic oil production. Meanwhile, Americans have expressed their discomfort with the war by dropping President Trump's approval rating to 41%, a term-low and down from 47% in January. The poll, conducted by Reuters and research firm Ipsos, showed that 84% of respondents were concerned about the war while 79% were worried that Americans could be attacked following the U.S. missile attack on Iran. In interest rate news, a second Fed member has voiced support for a July rate cut, sending the odds of a 25 basis points reduction to 22.7% compared to 14.5% yesterday on CME's FedWatch tool. Fed Governor Michelle Bowman said that she would support lowering rates as soon as July if inflation remains low. Last week, Fed Governor Christopher Waller said that the central bank is in a good position to cut rates as early as July. The S&P 500 finished with a 0.96% gain while the Nasdaq 100 returned 1.06%.
Yahoo
2 hours ago
- Yahoo
Novo Nordisk ends collaboration with Hims & Hers for discounted weight loss meds
Novo Nordisk said Monday it will end its collaboration with Hims & Hers that offered the weight loss medication Wegovy for patients who have a prescription for the medication but no insurance coverage for it. When the collaboration between Novo Nordisk and Hims & Hers was announced in April, Wegovy was made available on Hims through Novo Nordisk's NovoCare Pharmacy for a discounted price of $499 per month, in addition to Hims' monthly subscription fee. Hims has also continued to sell "personalized" doses of compounded semaglutide -- the main active ingredient in Wegovy -- for $165 per month, according to its website. Wegovy is approved by the U.S. Food and Drug Administration for weight loss in people with obesity or who are overweight with additional risks for cardiovascular disease. In explaining the decision to end the collaboration, Novo Nordisk alleged that Hims & Hers' has continued to offer compounded versions of Wegovy "under the false guise of 'personalization.'" "Novo Nordisk is firm on our position and protecting patients living with obesity. When patients are prescribed semaglutide treatments by their licensed healthcare professional or a telehealth provider, they are entitled to receive authentic, FDA-approved and regulated Wegovy," Dave Moore, Novo Nordisk's executive vice president of U.S. Operations, said in a news release Monday. "We will work with telehealth companies to provide direct access to Wegovy that share our commitment to patient safety -- and when companies engage in illegal sham compounding that jeopardizes the health of Americans, we will continue to take action." Wegovy to be sold on Hims, Ro and LifeMD for reduced price Hims & Hers' CEO Andrew Dudum said in a statement shared on X that the platform intends to continue to provide Wegovy for patients. "We are disappointed to see Novo Nordisk management misleading the public. In recent weeks, Novo Nordisk's commercial team increasingly pressured us to control clinical standards and steer patients to Wegovy regardless of whether it was clinically best for patients. We refuse to be strong-armed by any pharmaceutical company's anticompetitive demands that infringe on the independent decision making of providers and limit patient choice," Dudum said. "We take our role of protecting the ability of providers and patients to control individual treatment decisions extremely seriously, and will not compromise the integrity of our platform to appease a third party or preserve a collaboration. The health and wellness of individuals always comes first. He continued, "We will continue to offer access to a range of treatments, including Wegovy, to ensure providers can serve the individual needs of patients." Hims & Hers did not immediately reply to ABC News' request for further clarification about Wegovy remaining available on the platform. A spokesperson for Novo Nordisk told ABC News they have no additional comment. Compound drugs are copies of FDA-approved medications. They are made by licensed pharmacies, but not approved or inspected by the FDA. Drug compounding is allowed when drugs are on the FDA's shortage list, or in circumstances when a patient can't take a version of a drug made by a pharmaceutical company and they need an alternative. In recent months, Eli Lilly, the maker of Zepbound and Mounjaro, and Novo Nordisk, the maker of Ozempic and Wegovy, have each said they are able to meet the demand for the medications after facing shortages since 2022 due to the drugs' growing popularity. The FDA has declared the shortages as "resolved," removing the drugs from its shortage list. Super Bowl ad for Hims & Hers' weight loss drug sparks backlash Last week, a federal judge in Texas upheld the FDA's decision to remove semaglutide from the shortage list, blocking compounding pharmacies from making copies of Wegovy and Ozempic, according to court documents.
2 hours ago
Novo Nordisk ends collaboration with Hims & Hers for discounted weight loss meds
Novo Nordisk said Monday it will end its collaboration with Hims & Hers that offered the weight loss medication Wegovy for patients who have a prescription for the medication but no insurance coverage for it. When the collaboration between Novo Nordisk and Hims & Hers was announced in April, Wegovy was made available on Hims through Novo Nordisk's NovoCare Pharmacy for a discounted price of $499 per month, in addition to Hims' monthly subscription fee. Hims has also continued to sell "personalized" doses of compounded semaglutide -- the main active ingredient in Wegovy -- for $165 per month, according to its website. Wegovy is approved by the U.S. Food and Drug Administration for weight loss in people with obesity or who are overweight with additional risks for cardiovascular disease. In explaining the decision to end the collaboration, Novo Nordisk alleged that Hims & Hers' has continued to offer compounded versions of Wegovy "under the false guise of 'personalization.'" "Novo Nordisk is firm on our position and protecting patients living with obesity. When patients are prescribed semaglutide treatments by their licensed healthcare professional or a telehealth provider, they are entitled to receive authentic, FDA-approved and regulated Wegovy," Dave Moore, Novo Nordisk's executive vice president of U.S. Operations, said in a news release Monday. "We will work with telehealth companies to provide direct access to Wegovy that share our commitment to patient safety -- and when companies engage in illegal sham compounding that jeopardizes the health of Americans, we will continue to take action." Hims & Hers' CEO Andrew Dudum said in a statement shared on X that the platform intends to continue to provide Wegovy for patients. "We are disappointed to see Novo Nordisk management misleading the public. In recent weeks, Novo Nordisk's commercial team increasingly pressured us to control clinical standards and steer patients to Wegovy regardless of whether it was clinically best for patients. We refuse to be strong-armed by any pharmaceutical company's anticompetitive demands that infringe on the independent decision making of providers and limit patient choice," Dudum said. "We take our role of protecting the ability of providers and patients to control individual treatment decisions extremely seriously, and will not compromise the integrity of our platform to appease a third party or preserve a collaboration. The health and wellness of individuals always comes first. He continued, "We will continue to offer access to a range of treatments, including Wegovy, to ensure providers can serve the individual needs of patients." Hims & Hers did not immediately reply to ABC News' request for further clarification about Wegovy remaining available on the platform. A spokesperson for Novo Nordisk told ABC News they have no additional comment. Compound drugs are copies of FDA-approved medications. They are made by licensed pharmacies, but not approved or inspected by the FDA. Drug compounding is allowed when drugs are on the FDA's shortage list, or in circumstances when a patient can't take a version of a drug made by a pharmaceutical company and they need an alternative. In recent months, Eli Lilly, the maker of Zepbound and Mounjaro, and Novo Nordisk, the maker of Ozempic and Wegovy, have each said they are able to meet the demand for the medications after facing shortages since 2022 due to the drugs' growing popularity. The FDA has declared the shortages as "resolved," removing the drugs from its shortage list. Last week, a federal judge in Texas upheld the FDA's decision to remove semaglutide from the shortage list, blocking compounding pharmacies from making copies of Wegovy and Ozempic, according to court documents.
